Kymera Therapeutics, Inc. Common Stock (KYMR) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with KYMR
Recent news

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
KYMR

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
KYMR

Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.23
- MACD 12/26/9
- -1.86
- EMA 9 of MACD
- -1.53
- MACD histogram
- -0.33
- SMA 50
- $114.61
- Price below SMA 50
- EMA 50
- $112.32
- Price above EMA 50
- SMA 200
- $93.69
- Price above SMA 200
- EMA 200
- $94.78
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 10 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
KYMR

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
KYMR

Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMR

Kymera Therapeutics Q2 Earnings Call Highlights
Kymera Therapeutics Q2 Earnings Call Highlights
KYMR

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
KYMR

Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
KYMR

Kymera's CEO Sold $6 Million in Stock After a 170% Run
Kymera's CEO Sold $6 Million in Stock After a 170% Run
KYMR

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR

Why Kymera Therapeutics Stock Popped This Week
Why Kymera Therapeutics Stock Popped This Week
KYMR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Kymera Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director | 1979 |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer | — |
| Mr. Brian R. Adams J.D. | Chief Legal Officer & Corporate Secretary | 1974 |
| Dr. Jared A. Gollob M.D. | Advisor | 1965 |
| Mr. Noah Goodman M.B.A. | Chief Business Officer | 1987 |
| Ms. Justine E. Koenigsberg | Vice President of Investor Relations | — |
| Dr. Neil Graham M.D., M.P.H., MBBS | Chief Development Officer | 1959 |
| Mr. Brian Albarran M.B.A., Ph.D. | SVP of Corporate Strategy | — |
| Dr. Juliet Williams B.A Ph.D. | Head of Research | — |
| Dr. Jeremy G. Chadwick Ph.D. | Advisor | 1963 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 49.23
- MACD 12/26/9
- -1.86
- EMA 9 of MACD
- -1.53
- MACD histogram
- -0.33
- SMA 50
- $114.61
- Price below SMA 50
- EMA 50
- $112.32
- Price above EMA 50
- SMA 200
- $93.69
- Price above SMA 200
- EMA 200
- $94.78
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $115.00
- Average
- $142.33
- High
- $170.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +9.7 | -12.0 | +18.3 | |||||||||
| 2022 | -35.1 | -11.2 | +9.8 | -24.7 | -56.4 | +39.3 | +4.4 | +31.6 | -22.5 | +44.8 | -3.2 | -13.1 |
| 2023 | +50.5 | -14.2 | -7.6 | +6.2 | -6.5 | -21.8 | -7.2 | -12.0 | -30.0 | -14.0 | +79.7 | +22.6 |
| 2024 | +29.3 | +30.7 | -7.6 | -14.7 | -11.4 | -5.4 | +49.3 | +8.7 | +2.2 | -0.9 | +0.8 | -15.7 |
| 2025 | -3.2 | -18.6 | -9.3 | +35.8 | -14.2 | +1.2 | -1.6 | -4.1 | +39.1 | +13.1 | +13.7 | +16.4 |
| 2026 | -0.1 | +20.8 | -7.6 | -4.5 | +0.9 | +46.1 | -9.5 | +18.4 | -6.1 | +2.1 |



